StockNews.com lowered shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a buy rating to a hold rating in a research ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) will likely be announcing its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of $0 ...

Being included on the Forbes list is the latest accolade for the company. Last year, 84% of Myriad employees said it’s a Great Place To Work — 27 percentage points higher than the average U.S. company ...

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc.

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

盐湖城 - 年收入达8.24亿美元的基因检测和精准医疗公司Myriad Genetics, Inc. (NASDAQ: ...

Throughout the last three months, 8 analysts have evaluated Myriad Genetics (NASDAQ:MYGN), offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ...

SALT LAKE CITY, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, has been named on the Forbes list of ...

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management ...